Related Experiment Videos
Candidal costochondritis responsive to ketoconazole in an iv drug abuser
Abstract:
Infections caused by Candida albicans have been reported in many organ systems in intravenous drug users. Amphotericin B (Fungizone) has been shown to be effective in treatment. However, because of its numerous side effects and difficulty in maintaining intravenous access in this population, the agent is difficult to use. Ketoconazole (Nizoral), administered orally, is a more convenient and better tolerated agent and was efficacious in the case of candidal costochondritis described here. Further evaluation of ketoconazole is needed to better define its role in the treatment of disseminated candidiasis, particularly in cases associated with intravenous drug abuse.
Insights
Candida albicans infections are common in intravenous drug users. Oral ketoconazole offers a more convenient and effective treatment option compared to intravenous amphotericin B, with fewer side effects.
Area of Science:
- Mycology
- Infectious Diseases
- Pharmacology
Background:
- Disseminated Candida albicans infections pose significant challenges, particularly in intravenous drug users.
- Intravenous amphotericin B is effective but limited by severe side effects and administration difficulties in this population.
Observation:
- A case of candidal costochondritis in an intravenous drug user is presented.
- The patient was treated with oral ketoconazole.
Findings:
- Oral ketoconazole demonstrated efficacy in treating candidal costochondritis.
- Ketoconazole offers a more convenient and better-tolerated alternative to intravenous amphotericin B.
Implications:
- Ketoconazole may be a valuable therapeutic option for disseminated candidiasis in intravenous drug users.
- Further research is warranted to establish the role of ketoconazole in managing these complex infections.